CalciMedicaNASDAQ: CALC

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

14 June 2023

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$46.01 M
-38%vs. 3y high
34%vs. sector
-vs. 3y high
-vs. sector
-63%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | 16 min ago
$4.28+$0.28(+7.00%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CALC Latest News

CalciMedica Announces Proposed Public Offering of Common Stock
prnewswire.com30 October 2024 Sentiment: -

LA JOLLA, Calif. , Oct. 30, 2024 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it has commenced an underwritten public offering of its shares of common stock.

CalciMedica Announces Upcoming Late-Breaker Plenary Presentation at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting
prnewswire.com16 October 2024 Sentiment: POSITIVE

LA JOLLA, Calif. , Oct. 16, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the acceptance of a late-breaking abstract for a plenary presentation by Prof.

CalciMedica to Present at the H.C. Wainwright 26th Annual Global Investment Conference
prnewswire.com03 September 2024 Sentiment: POSITIVE

LA JOLLA, Calif. , Sept. 3, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.

CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora™ in Severe Acute Kidney Injury (AKI)
prnewswire.com09 July 2024 Sentiment: POSITIVE

Development of Auxora in AKI is supported by both clinical and pre-clinical evidence Topline data expected in 2025 LA JOLLA, Calif. , July 9, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the first patient has been dosed in KOURAGE, the Company's Phase 2 trial evaluating Auxora™ for the treatment of severe acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).

CalciMedica Announces Presentations at Two Upcoming Healthcare Investment Conferences
prnewswire.com08 July 2024 Sentiment: POSITIVE

LA JOLLA, Calif. , July 8, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("CRAC") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D.

CalciMedica to Host Conference Call to Review Topline Data from Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis (AP)
prnewswire.com26 June 2024 Sentiment: POSITIVE

Conference call and webcast to be held tomorrow, June 27, 2024 at 8:30 a.m. ET/ 5:30 a.m.

What type of business is CalciMedica?

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

What sector is CalciMedica in?

CalciMedica is in the Healthcare sector

What industry is CalciMedica in?

CalciMedica is in the Biotechnology industry

What country is CalciMedica from?

CalciMedica is headquartered in United States

When did CalciMedica go public?

CalciMedica initial public offering (IPO) was on 14 June 2023

What is CalciMedica website?

https://www.calcimedica.com

Is CalciMedica in the S&P 500?

No, CalciMedica is not included in the S&P 500 index

Is CalciMedica in the NASDAQ 100?

No, CalciMedica is not included in the NASDAQ 100 index

Is CalciMedica in the Dow Jones?

No, CalciMedica is not included in the Dow Jones index

When was CalciMedica the previous earnings report?

No data

When does CalciMedica earnings report?

The next expected earnings date for CalciMedica is 08 November 2024